Video

Dr. Landgren on Maintenance Therapy in Myeloma

Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, discusses the pros and cons of maintenance therapy for patients with myeloma.

Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, discusses the pros and cons of maintenance therapy for patients with myeloma.

Maintenance therapy in myeloma, Landgren says, is not new, as studies have analyzed steroids, interferon, thalidomide, lenalidomide, and proteasome inhibitors. Several studies have demonstrated progression-free survival advantage with maintenance therapy.

One study, with lenalidomide, showed overall survival advantage but also severe side effects. Patients treated with lenalidomide had an increased risk of developing a secondary hematologic malignancy than with placebo, though the risk was not great. Though lenalidomide can provide overall survival advantage, a secondary hematologic malignancy would be devastating to a patient.

Related Videos
Sheldon M. Feldman, MD
Rita Mukhtar, MD
Lajos Pusztai, MD, DPhil
Hope S. Rugo, MD
Marc Machaalani, MD
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Alfred L. Garfall, MD, MS
Razane El Hajj Chehade, MD
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School